<DOC>
	<DOCNO>NCT00681603</DOCNO>
	<brief_summary>1 . Purpose : Our animal study demonstrate effectiveness subconjunctival injection bevacizumab inhibition corneal neovasculization formation . The purpose human interventional study report treatment outcome subconjunctival injection bevacizumab patient corneal neovascularization . 2 . Material method : We enrol 13 patient unilateral bilateral clinically significant corneal neovascularization Aug. 2007 Jan. 2008 . Subconjunctival injection bevacizumab per month 7 time perform accord clinical response . 3 . Main outcome measurement : resolution corneal neovascularization , reduction lipid infiltrate , improve visual acuity .</brief_summary>
	<brief_title>Safety Effectiveness Subconjunctival Injection Bevacizumab Treatment Corneal Neovasculization</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Significant unilateral bilateral corneal neovascularization extend limbus least 2mm The underlying etiology cause corneal neovascularization include post penetrating keratoplasty ( PKP ) , trauma , infectious noninfectious corneal ulcer , postkeratoplasty , etc . Corneal neovascularization induce lipid keratopathy , corneal edema , irregular corneal surface . The bestcorrected visual acuity le 20/25 PostPKP corneal neovascularization associate lipid keratopathy , corneal edema , corneal irregularity . But neovascularization highly possible cause graft rejection . The corneal neovascularization refractory medical treatment The patient receive PKP corneal surgery half year ago acute postoperation phase The patient active endopthalmitis , glaucoma uncontrolled intraocular pressure , vitreoretinal diseases The patient sign inform consent regular follow treatment The neovascularization clinical improvement three month first injection The lipid keratopathy clinical improvement three month first injection The patient suspect poor visual outcome already light sense negative Glaucoma patient uncontrolled intraocular pressure Poor corneal epithelialization PostPKP patient graft failure rejection Patient systemic disease suitable bevacizumab use Pregnant patient</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>corneal neovascularization</keyword>
	<keyword>lipid keratopathy</keyword>
	<keyword>penetrate keratopathy</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>subconjunctival injection</keyword>
</DOC>